Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.

Carl ErikssonJonas SöderlingSara KarlqvistGabriella BrömsÅsa H EverhovDaniel BergemalmJonas F Ludvigssonnull nullOla OlénJonas Halfvarson

Published in: Digestive diseases and sciences (2023)

Based on data from Swedish routine care, no clinically relevant differences in effectiveness or safety of second-line ustekinumab vs anti-TNF treatment were observed in patients with CD with prior exposure to anti-TNF.

Keyphrases

rheumatoid arthritis
healthcare
randomized controlled trial
palliative care
systematic review
big data
electronic health record
clinical practice
machine learning
quality improvement
pain management
combination therapy
deep learning
replacement therapy
data analysis